| Revenue Growth | China 31% (adj), Americas 14%, EMEA 31%, APAC ex-China 4%. |
|---|---|
| Mgmt Confidence | Confident in long-term laser-to-lens shift; cautious on near-term macro/geopolitical outlook. |
| Demand Visibility | China in-market unit shipments grew 12.4%; supply unable to meet demand. |
| Order Book | Distributor inventory below six-month target; working through US MTO backlog. |
| Margin Trends | Q3 gross margin 70.9% vs 75.5% (adj); temporary ERP/tariff pressures. |
| Op. Leverage | Yield improvements of 1% generate $750k-$1M in annual incremental profit. |
| Pricing Power | Higher ASPs driven by mix shift to EVO Plus and Toric. |
| Vol vs Price | China net sales growth entirely price/mix-led due to supply constraints. |
| Segment Growth | EVO Plus and Toric lenses driving premium mix and ASP growth. |
| New Clients | Hundreds of mid-tier Chinese hospitals closing gap with established centers. |
| Capex & Debt | Debt-free; $206.4M cash; $50M share repurchase program authorized. |
| Regulatory | Awaiting regulatory authorizations for first-in-human Presbyopia trials; US label expanded. |
| Commentary | Strategic focus on 'Innovation Acceleration' across product, commercial, and operational areas. |
| New Launches | EVO Plus launched in China; two Presbyopia products entering human trials. |
Growth
Excluding China deferred sales, Q3 net sales grew 21%; China grew 31% and Americas 14%.
Outlook
Expects 2027 gross margin improvement; authorized $50 million share repurchase; Presbyopia trials starting in months.
Risks
Management used vague language regarding Q4 guidance and 2027 outlook, citing macro and geopolitical unknowns.
The company's earnings call, NASDAQ: STAA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Staar Surgical Co: key numbers
- Share price
- $26.01Close, Nov 16
- Market cap
- $1.31B
- Shares outstanding
- 50.2MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Ophthalmic GoodsSIC 3851
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Staar Surgical Co
All →Staar Surgical Q3 2026 Results: Net Income $5.58M, Down 37.2% YoY
STAAR Surgical reported net income of $18.8 million for the first nine months of 2026, a significant recovery from a net loss of $62.1 million in the prior year period. Net sales grew to $270.5 million from $181.6 million year-over-year, driven by improved operating income and reduced restructuring and impairment charges.
- Key figure
- Net income $5.58M · -37.2% YoY
Staar Surgical Financial Results
STAAR Surgical reported third quarter 2026 net sales of $83.4 million and net income of $5.6 million. The company achieved record year-to-date revenue of $270.5 million and authorized a new $50 million share repurchase program during the period.
- Term
- Q3 2026
Staar Surgical Executive Compensation
STAAR Surgical Company appointed former CEO David Bailey as Chief Commercial Officer, effective September 8, 2026. His compensation package includes an annual base salary of approximately $575,000, a target cash bonus of 60% of base salary, and initial equity grants totaling $2.25 million in value (comprised of an $850,000 sign-on grant and a $1.4 million annual long-term incentive award).
- Counterparty
- David Bailey